Navigation Links
Takeda Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
Date:11/1/2011

stry of Health, Labour, and Welfare for the treatment of type 2 diabetes, and the therapy is currently available under the brand name NESINA® in this market.

Alogliptin/pioglitazone is a fixed-dose combination therapy in development for the treatment of type 2 diabetes, which combines alogliptin and pioglitazone in a single tablet. Pioglitazone is a TZD that directly targets insulin resistance, a condition in which the body does not efficiently use the insulin it produces to control blood glucose levels, and is approved in adults for the treatment of type 2 diabetes as an adjunct to diet and exercise. An NDA for the alogliptin/pioglitazone fixed-dose combination was approved in July 2011 by the Japanese Ministry of Health, Labour and Welfare for the treatment of type 2 diabetes, and the therapy is currently available under the brand name LIOVEL® in this market.

Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc.

Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia, rheumatology, and gastroenterology and cardiovascular treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for metabolic and cardiovascular disease, gastroenterology, neurology and other conditions. To learn more about these Takeda companies, visit www.tpna.com.


'/>"/>
SOURCE Takeda Global Research & Development Center, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
2. Takeda Completes Acquisition and Names New CEO of Nycomed
3. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
4. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
5. Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of ACTOS (pioglitazone HCl)
6. Takeda to Acquire Nycomed
7. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
8. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
9. Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takedas DEXILANT®
10. Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
11. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... , May 18, 2013 Faruqi ... firm, is investigating potential securities fraud at AVEO ... (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... and its executives violated federal securities laws by ... Company,s Phase III drug trials for Tivopath (tivozanib) ...
(Date:5/17/2013)... , May 17, 2013  Orexigen® Therapeutics, Inc. (Nasdaq: ... company overview at the UBS Global Healthcare Conference in ... Wednesday, May 22 nd at 11 a.m. Eastern Time. ... the presentation, please visit the Investor Relations section of the ... be available for 14 days after the event. ...
(Date:5/17/2013)... YORK , May 17, 2013 /PRNewswire-iReach/ -- United ... Advanced Cardiac Life Support (ACLS), Pediatric Advanced Life Support ... free PALS, BLS and ACLS online course ... manuals, people simply need to build an account with ... materials for these programs, United Medical Education is setting ...
Breaking Medicine Technology:Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2ACLS Online Course Manuals are Now Available at No Cost through United Medical Education 2
... BETHESDA, Md., April 14 Micromet, Inc.,(Nasdaq: ... novel, proprietary,antibodies for the treatment of cancer, ... meeting of the American Association for,Cancer Research ... that commercial,anti-cancer antibodies trastuzumab (Herceptin(R); Genentech, Roche),cetuximab ...
... the, Tumor Suppressor P53 Inhibited Tumor Growth Synergistically in Preclinical ... ... 14 ,Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) announced today that ... 2008 Annual Meeting of the American Association for Cancer Research,(AACR) further ...
Cached Medicine Technology:Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 2Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 3Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 4Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 5Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies 2Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies 3Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies 4
(Date:5/18/2013)... HealthDay Reporter , , FRIDAY, May 17 (HealthDay News) -- ... of what is considered the "bible" of modern psychiatry ... "This is unprecedented, the amount of commentary and ... the American Psychiatric Association (APA). "It,s been an interesting ... have to evaluate it and then make your own ...
(Date:5/18/2013)... Orlando, FL (May 18, 2013) There are ... procedures commonly used to diagnose or treat gastrointestinal ... Week (DDW). , A study by New ... that more objective testing may substantially reduce the ... (GERD). Although GERD is believed to affect nearly ...
(Date:5/18/2013)... 18, 2013 Today, Zane Benefits, ... agents’ role in Marketplaces . Zane Benefits, which ... sponsored health benefits, is the leader in health ... health reimbursement arrangements . , According to Zane ... Services (HHS) recently released a much-anticipated statement and ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 After working diligently ... SizeItUp formally announced the integration of the fitment ... Hyundai Genesis is set to stun the automobile market with ... 2012 Hyundai Genesis is marked as the latest entry in ... the vehicles lined up for the year 2013. , ...
(Date:5/18/2013)... Although obesity is associated with an increased risk ... esophageal adenocarcinoma, a type of esophageal cancer, is stronger ... on Cancer.gov, last reviewed in January 2012, overweight ... those of normal and healthy weight to develop this ... cancer is not well understood, it is now thought ...
Breaking Medicine News(10 mins):Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 2Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 3Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 4Health News:New research identifies practice changes to improve value and quality of GI procedures 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 3
... NY - In an important finding published online in ... of Medicine of Yeshiva University, along with collaborators at ... responsible for causing breast cancer to spread. , ... tumor travel to distant sites via the blood system. ...
... to identify a disease whether it is common ... people think the condition is, according to new research ... study on how people understand and interpret disease. ... Public Library of Science: ONE , examined many recently ...
... to Phase 3 trials following the successful trial of the ... Korogwe, Tanzania and coastal Kenya, which is reported today in ... , In a separate paper, which also appears in the ... co-administration of the RTS, S/AS02 malaria vaccine through the WHO ...
... , ... (Vocus) December 8, 2008 -- Losing a child to the ... , it is a tragedy they have experienced firsthand. The nonprofit organization ... the flu or have had a child experience severe medical complications from ...
... WASHINGTON, Dec. 8 The independent, non-profit, ... medical records for every doctor,s office and hospital ... key elements of which were announced as part ... Address ( http://change.gov/newsroom/entry/the_key_parts_of_the_jobs_plan/ ). , ...
... saves hospitals time, increases accuracy of medication supply, and ... , ORLANDO, Fla., Dec. 8 ... solutions for hospital supply chain logistics, announced today at ... that it has developed a patent-pending replenishment solution for ...
Cached Medicine News:Health News:Einstein researchers discover protein that contributes to cancer spread 2Health News:Einstein researchers discover protein that contributes to cancer spread 3Health News:Medical terms worry more people than lay terms, study finds 2Health News:Promising trials of malaria vaccine lead to calls for Phase 3 development 2Health News:Promising trials of malaria vaccine lead to calls for Phase 3 development 3Health News:For Kids, the Flu Can Be Severe, Even Deadly 2Health News:For Kids, the Flu Can Be Severe, Even Deadly 3Health News:eHealth Initiative Applaudes President-Elect Obama's Recognition of the Importance of Information Technology to Improve U.S. Health Care System 2Health News:Aethon Develops First-Ever Solution for Automated Replenishment of Pharmacy ADCs 2Health News:Aethon Develops First-Ever Solution for Automated Replenishment of Pharmacy ADCs 3
... The Brasseler USA™ Battery Packs contain ... age have a great impact upon battery ... is necessary. Any deviation from these recommendations ... are sensitive to heat. Any exposure of ...
... Brasseler USA™ Battery Packs contain rechargeable nickel ... a great impact upon battery life. Strict ... Any deviation from these recommendations will shorten ... to heat. Any exposure of the Battery ...
Pneumatic High-speed Drill, 90k Rpm, With Microaire Hose Connector....
... powered system, offers precision with ease ... procedures. The system can be utilized ... oral, maxillofacial, podiatric and otology techniques. ... a high speed drill, low speed ...
Medicine Products: